Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.

about

Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.

Item

http://www.wikidata.org/entity/Q47759603

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Formulation of the bivalent pr ...... cells in PSA-transgenic mice.

@en

Formulation of the bivalent pr ...... cells in PSA-transgenic mice.

@nl

type

Item

label

Formulation of the bivalent pr ...... cells in PSA-transgenic mice.

@en

Formulation of the bivalent pr ...... cells in PSA-transgenic mice.

@nl

prefLabel

Formulation of the bivalent pr ...... cells in PSA-transgenic mice.

@en

Formulation of the bivalent pr ...... cells in PSA-transgenic mice.

@nl

P1476

Formulation of the bivalent pr ...... cells in PSA-transgenic mice.

@en

P2093

Dev Karan

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Adenoviruses as vaccine vectors.

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Breaking tolerance in cancer immunotherapy: time to ACT.

Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge

Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

P304

5794-5798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2017.09.037

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28939158

http://www.w3.org/2001/XMLSchema#string

P932

5617798

http://www.w3.org/2001/XMLSchema#string